Glumasetide (name verification and likely correspondence)
“Glumasetide” could not be confirmed in available FDA-labeled or PubMed-indexed sources during web review, so drug-specific indications and safety cannot be verified for that exact name. The spelling “Glumasetide” is plausibly associated with teduglutide brand GATTEX for gastrointestinal disease in adults, which has a defined safety profile and labeled monitoring requirements. [1], [2]
Indicated gastrointestinal condition in adults (teduglutide)
Teduglutide is indicated for treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral nutrition. [1]
Appropriate use principles
Teduglutide should be reserved for patients matching the labeled gastrointestinal indication for adult SBS with parenteral nutrition dependence. [1] Use should include medication reconciliation for interacting oral therapies because enhanced absorption of concomitant oral medications is a labeled risk. [1]
Contraindications and key warnings (neoplasia risk)
Teduglutide has a labeled warning for acceleration of neoplastic growth. [1] Teduglutide therapy should be discontinued in patients with active gastrointestinal malignancy. [1] Clinical decisions for patients at increased malignancy risk should weigh benefit versus risk before initiating therapy. [1]
Safety monitoring requirements
Colonoscopy of the entire colon with removal of polyps is recommended within 6 months before starting teduglutide. [3] Follow-up colonoscopy (or alternate imaging) is recommended at the end of 1 year of therapy. [3] Subsequent colonoscopies are recommended every 5 years or more often as needed. [3] Patients should undergo ongoing monitoring for neoplastic risk and for adverse reactions requiring diagnostic follow-up. [1]
Gastrointestinal adverse effects and other clinically important adverse effects
Teduglutide can cause injection-site reactions including skin problems at the injection site. [2] Teduglutide can cause rash and pruritus-type reactions. [2] Teduglutide is associated with potential serious adverse events involving abnormal stool changes, abdominal pain or swelling, fever, and hepatobiliary-type warning symptoms such as jaundice symptoms. [2]
Drug–drug safety considerations
Teduglutide can increase absorption of some concomitant oral medications, which can require dose reduction of the interacting oral drug in patients on narrow therapeutic index therapies or drugs requiring titration. [1] Altered mental status has been observed in adult patients using concomitant benzodiazepines in clinical studies, so monitoring for adverse reactions related to concomitant drugs is recommended during coadministration. [1]
Renal impairment and administration-related safety
Teduglutide dosing requires adjustment in renal impairment, with 50% dose reduction recommended for moderate to severe renal impairment and end-stage renal disease. [3] Fluid and electrolyte status can be affected with discontinuation of teduglutide, so monitoring is recommended when stopping therapy. [3] Teduglutide requires reconstitution and limited use time after reconstitution, consistent with labeled preparation instructions. [3]
Clinical information needed to confirm safe use for “Glumasetide”
Exact active ingredient and formulation should be verified through the medication label because “Glumasetide” could not be validated as a distinct agent in review sources. [1], [2] If teduglutide is confirmed, the labeled adult SBS-with-parenteral-nutrition indication, neoplasia monitoring schedule, and oral drug absorption monitoring should be applied to determine appropriateness and safety. [1], [2], [3]
Targets of therapy for gastrointestinal outcomes (teduglutide)
A labeled therapeutic goal in adult SBS is reduction in dependence on parenteral nutrition, consistent with the indication for SBS patients dependent on parenteral nutrition. [1]